Daniel Zuckerbrod, MD
Ophthalmology · Detroit, MINPI 1033104773
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 648 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by Alimera Sciences, Inc. at 25.9% of the total. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 648 payments — averaging $24.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$4K
- AbbVie$2K
- Alcon$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Bausch & Lomb Americas Inc.$912
- Aerie Pharmaceuticals, Inc.$801
- plus $5K from 29 others
Across 2 payments — averaging $240.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$481
What the payments were for
- Food & beverage$15,99499%
- Education$800%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 21 | $4,165 |
| AbbVie(2 entities) | 112 | $2,248 |
| Alcon | 57 | $1,540 |
| Regeneron Healthcare Solutions, Inc. | 41 | $1,216 |
| Bausch & Lomb Americas Inc. | 75 | $912 |
| Aerie Pharmaceuticals, Inc. | 84 | $801 |
| Amgen | 33 | $668 |
| Sight Sciences, Inc. | 45 | $583 |
| Novartis | 22 | $532 |
| Oyster Point Pharma, Inc. | 12 | $352 |
| Apellis Pharmaceuticals, Inc. | 8 | $313 |
| Eyevance Pharmaceuticals LLC | 12 | $297 |
| Tarsus Pharmaceuticals, Inc. | 14 | $293 |
| Rxsight Inc | 5 | $279 |
| Glaukos Corporation | 5 | $263 |
| Kala Pharmaceuticals, Inc. | 11 | $250 |
| Sun Pharmaceutical Industries Inc. | 12 | $232 |
| Mallinckrodt Hospital Products Inc. | 11 | $170 |
| Shire North American Group Inc | 22 | $149 |
| Harrow Eye, LLC | 8 | $138 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $108 |
| NEW World Medical,inc. | 8 | $85 |
| Genentech USA, Inc. | 4 | $80 |
| Ivantis, Inc | 1 | $76 |
| Biotissue Holdings Inc. | 3 | $75 |
| Maculogix, Inc. | 3 | $55 |
| LKC Technologies, Inc. | 2 | $36 |
| Dompe US, Inc. | 2 | $31 |
| Rayner Intraocular Lenses Limited | 2 | $30 |
| Thea Pharma Inc. | 2 | $30 |
| Tearlab Corp | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $15 |
| Eyepoint US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iluvien$3,970
- Rhopressa$600
- Rocklatan$600
- Hydrus Microstent$360
- DURYSTA$351
- YUTIQ$300
- EYLEA HD$240
- RXSIGHT CONTACT LENS$238
- RXSIGHT INJECTOR CARTRIDGE$238
- RXSIGHT INJECTOR HANDPIECE$238
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$238
- LIGHT ADJUSTABLE LENS (LAL)$238
- TEPEZZA$236
- SIMBRINZA$150
- Tobradex ST$139
- OMNI(R) SURGICAL SYSTEM (US)$129
- OZURDEX$125
- MIEBO$123
- XIIDRA$123
- TYRVAYA$122
How this compares
$16,093 in reported general payments places this provider in the 95th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 717 | $471,900 |
| MieboPerfluorohexyloctane/Pf | 194 | $151,306 |
| XiidraLifitegrast | 165 | $123,983 |
| LumiganBimatoprost | 294 | $94,386 |
| RocklatanNetarsudil Mesylat/Latanoprost | 205 | $80,549 |
| Cyclosporine | 233 | $72,267 |
| RhopressaNetarsudil Mesylate | 140 | $48,836 |
| XdemvyLotilaner | 24 | $44,745 |
| VyzultaLatanoprostene Bunod | 90 | $33,610 |
| Brimonidine Tartrate | 569 | $33,599 |
| Alphagan PBrimonidine Tartrate | 95 | $27,827 |
| Prednisolone Acetate | 511 | $26,574 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 111 | $23,622 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 109 | $16,233 |
| CombiganBrimonidine Tartrate/Timolol | 44 | $13,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $2,248 | $607,3461,150 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta, Zirgan | $912 | $318,699470 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $801 | $129,386345 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $293 | $44,74524 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex, Lotemax, Loteprednol Etabonate, Besivance | $108 | $35,728119 claims |
| AlconSimbrinza | $1,540 | $23,622111 claims |
| Eyevance Pharmaceuticals LLCZerviate, Flarex | $297 | $9,62947 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $232 | $6,71412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 674 ophthalmology providers in Michigan.
Other ophthalmology in Detroit
- Bret HughesDetroit$123K
- Pradeepa YoganathanDetroit$115K
- Michael ColemanDetroit$20K
- Daniel AppleDetroit$10K
- Gabriel SosneDetroit$9K
- Manjool ShahAnn Arbor$609K
- Gregory KatzYpsilanti$401K
- Timothy PageBirmingham$250K
- David ZacksAnn Arbor$177K
- Scott WesthouseGrand Rapids$138K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.